Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAIN: Rebif Maintenance in MS After Mitoxantrone
NCT01142466Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2005
- Primary completion
- Dec 2009
- Modality
- Cytokines & Interferons
01
Overview
Phase 4, randomised, open-label trial of interferon beta-1a in multiple sclerosis (MS) (2 arms), sponsored by Merck KGaA. Primary endpoint: Time From Baseline to First Multiple Sclerosis Relapse at 96 weeks. Started Dec 2005; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01142466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142466.